1
                                                                     EXHIBIT 99


RESPONSE TECHNOLOGIES, INC. ANNOUNCES
REVERSE STOCK SPLIT; MOVE TO NASDAQ NATIONAL
MARKET; NAME CHANGE; ENGAGEMENT OF SMITH BARNEY;
AND PLANS TO ACQUIRE PHYSICIAN PRACTICES



MEMPHIS, TENNESSEE (October 23, 1995) --Response Technologies, Inc. today
announced plans to effect a one-for-five reverse stock split of its common
stock; delist its common stock from the American Stock Exchange (AMEX:RTK) and
begin trading on the Nasdaq National Market under the symbol ROIX starting
Thursday, October 26, 1995; and change its name from "Response Technologies,
Inc." to "Response Oncology, Inc." The aforementioned reverse stock split and
name change are contingent upon approval by a majority of shareholders at a
Special Meeting of Shareholders to be held on November 1, 1995, and pending
such approval will take effect November 2, 1995.  In addition, the Company
announced that it has retained Smith Barney Inc. to assist in the development
of a physician practice acquisition and management strategy, including the
development of financing alternatives for such contemplated acquisitions.

William H. West, M.D., CEO, stated "The reverse stock split and the move to the
Nasdaq National Market help to better position the Company with respect to the
capital markets. The name change to Response Oncology reflects the focus of the
Company.  More importantly, we are very excited by the prospects of expanding
our relationships with some of our oncologists in the high dose chemotherapy
programs to include acquisition and management of their practices.  Response's
data collection, analysis and outcomes reporting relative to advanced cancer
therapies provides a natural segue into information management of the full
spectrum of cancer care.  These disease management capabilities will provide a
significant competitive advantage to our groups in winning managed care
contracts." Dr. West continued "We have entered into a letter of intent to
purchase and manage the assets of a leading oncology-hematology paractice, and 
we expect that further acquisitions will be forthcoming.  The Company is
currently evaluating means of optimally financing these acquisitions, and it is
contemplated that such acquisitions will be financed through combinations of
cash, debt, and equity.  However, there are no assurances that the Company will
successfully consummate the acquisition of this or any additional practices."
Dr. West concluded "We are affiliated with over 300 oncologists in 21 states
through our stem cell program, presenting us with an entree to potential
acquisition relationships."

Response Technologies owns and operates a network of specialized outpatient
treatment centers, or IMPACT(R) Centers, which provide advanced cancer
treatment services under the direction of practicing oncologists.

The common stock of Response Technologies, Inc. is currently traded on the
American Stock Exchange (AMEX) under the symbol RTK.  On October 26, 1995, the
common stock will begin trading on the Nasdaq National Market under the symbol
ROIX.  Effective November 2, 1995 (subject to shareholder approval), the common
stock will trade under the symbol ROIXD for an interim period to denote
occurrence of the one-for-five reverse stock split.


                                  * * * * *